Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 4/20 | 0.57 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 7/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.37 |
| ▸ | CCND1 | P24385 | 2/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.35 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.35 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.35 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.35 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1042556 | 0.86 | MAPKAPK5 (0.61) | MAPKAPK5INSR | |
| SCHEMBL1046703 | 0.86 | MAPKAPK5 (0.75) | MAPKAPK5ACVR1KDRBMPR1BBMPR1A | |
| SCHEMBL10134440 | 0.84 | MAPKAPK5 (0.56) | MAPKAPK5ACVR1HRH3CDK4CDK6 | |
| SCHEMBL1478109 | 0.84 | MAPKAPK5 (0.78) | MAPKAPK5ACVR1HRH3KDRBMPR1B | |
| SCHEMBL1046099 | 0.82 | MAPKAPK5 (0.58) | MAPKAPK5HRH3CDK2CCNE1CDK4 | |
| SCHEMBL1045286 | 0.81 | MAPKAPK5 (0.56) | MAPKAPK5ACVR1CDK2CCNE1FLT3 | |
| SCHEMBL1044786 | 0.81 | ACVR1 (0.42) | MAPKAPK5ACVR1HRH3FGFR1KDR | |
| SCHEMBL1046040 | 0.81 | HRH3 (0.44) | MAPKAPK5HRH3FLT3CDK4CDK6 | |
| SCHEMBL1044262 | 0.80 | CDK4 (0.41) | HRH3CDK2CCNE1CDK4CDK6 | |
| SCHEMBL1048035 | 0.79 | MAPKAPK5 (0.57) | MAPKAPK5HRH3CDK2CCNE1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | claimed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | claimed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| EP-2086540-B1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| EP-2086540-B1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | COL2A1, MMP1, COL1A1 | MAPKAPK5 15/4885ACVR1 332/4885HRH3 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.